bodyType

customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

hooksAmpRedirectArticle

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

paywallTypes

createdDate

publishedDate

sponsorType

urlAlias

moreOnThisArticles

commentCount

authorLocations

authors

corrections

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

articleSpeeches

socialHeadline

headline

images

flag

firstTopic

glossary

flattenTypeIds

image

relatedLinks

relatedNewsletters

__typename

sponsor

pdfFiles

seriesReverseOrder

series

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

readingTime

customTimezone

liveContents

Germany's economy minister has a message for the United States in a row that has emerged over coronavirus vaccine access: “Germany is not for sale.”
Minister Peter Altmaier, a close ally of Chancellor Angela Merkel, delivered the message in English on Monday in a podcast hosted by prominent German journalist Gabor Steingart.
Citing government sources in Berlin, the Sunday edition of the mass-circulation Die Welt newspaper reported that the US had offered CureVac, a private firm based in Tuebingen, 30km (19 miles) south of Stuttgart, US$1 billion for exclusive rights to a vaccine that it is developing.
“We know this company, [and] we are in touch with this company,” Altmaier said in the podcast interview, which was conducted in German.


However, CureVac denied that any offer had been made.
“CureVac has not received from the US government or related entities an offer before, during and since the Task Force meeting in the White House on March 2. CureVac rejects all allegations from [the] press,” the company said in a tweet.
A CureVac spokesperson would not give details about last week's surprise change in management, which saw Daniel Menichella replaced as chief executive by CureVac founder Ingmar Hoerr.
Europe to shut border for month in response to coronavirus pandemic
In early March Menichella, a US citizen, visited the White House at the invitation of President Donald Trump to discuss strategies for vaccine development, together with other pharmaceutical and biotech companies.
CureVac is currently working on a coronavirus vaccine and has received US$8.3 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI), an international alliance.
Once a suitable vaccine has been found and tested in clinical trials, CureVac intends to produce the drug itself.
According to the company spokesperson, it is not clear whether CureVac would sell the rights to the vaccine, conclude an external contract or market the drug itself.


“We are not bound by any agreements,” he said.
European Commission President Ursula von der Leyen spoke with executives from the German pharmaceutical company on Monday, writing on Twitter that the European Union would offer financial support to the firm as it had done in the past.
It is “crucial to find a vaccine that will help the whole world”, she wrote.
Coronavirus: Canada shuts borders to non-citizens and non-residents
Despite the company's denial of any US offer, German government ministers were quick to confirm that they had been informed about the reported sum.
“German researchers are leaders in the development of medicines and vaccines, in global collaborations. We cannot allow others to exclusively acquire their research results,” Foreign Minister Heiko Maas told the newspapers of the Funke media group.
“We will only defeat this virus together, not against each other,” Maas asserted.


Hong Kong’s Peninsula Hotels sees ‘bleisure’ boom after pandemic curbs, CEO says

US could require US$15,000 bonds for some tourist, business visas

China’s Shenzhen, Guangzhou airports hit record highs, surpass pre-Covid passenger levels

Landmark US Chinatown survived Covid, anti-Asian violence – but tariffs pose new threat

Coronavirus pandemic

Coronavirus: ‘Germany not for sale,’ says minister after ‘US tried to buy vaccine rights’

An employee at German biopharmaceutical company CureVac demonstrates research workflow on a vaccine for Covid-19 a laboratory in Tuebingen, Germany, on Thursday. Photo: Reuters

Coronavirus: Donald Trump trying to poach German scientists working on experimental vaccine, report claims

A researcher at Protein Sciences works in a lab in Meriden, Conn. Photo: AP Photo

A researcher at Protein Sciences moves a vial in a lab, Thursday, March 12, 2020, in Meriden, Conn. The biotech company is currently researching a vaccine for COVID-19. For most people, the new coronavirus causes only mild or moderate symptoms, such as fever and cough. For some, especially older adults and people with existing health problems, it can cause more severe illness, including pneumonia. The vast majority of people recover from the new virus. (AP Photo/Jessica Hill)

Hopes for coronavirus vaccine rise after Chinese scientists find infected monkeys developed immunity

Rhesus monkeys were infected with Covid-19 as part of the experiment. Photo: AFP/ Getty Images

Coronavirus latest: new urgency in global ‘war’ against pandemic

Spain officially became the fourth-most infected country in the world, surpassing South Korea. Photo: Reuters

News

World

Europe

United States & Canada


US allegedly offered local firm CureVac US$1 billion for exclusive rights to vaccine, according to German newspaper
Company denies receiving offer from US government and declines to give details about surprise change in CEO



US allegedly offered local firm CureVac US$1 billion for exclusive rights to vaccine, according to German newspaper.
